NewsMV
A wide gap between Patrick Soon-Shiong's public proclamations about his cancer therapies and what clinical evidence actually shows is drawing renewed criticism, according to a STAT+ Biotech Scorecard investigation.
The billionaire physician and entrepreneur has faced FDA reprimands and accusations that his statements about his cancer drugs' potential are financially self-serving — even as a vocal online following defends him as a selfless scientist.
The Promise-vs-Delivery Problem STAT+'s analysis centers on what it describes as a pattern of proclamations that have not been matched by real clinical results.
The newsletter characterizes Soon-Shiong's public statements as "mostly fluff" and finds them to have triggered at least one FDA wrist-slapping.
Keep reading